The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement
Our study provides insight into the overall impact of the patient journey on their quality of life and demonstrates how increased awareness of ATTRwt amyloidosis and more coordinated engagement with physicians could reduce the time to diagnosis.
Authors
- Madeline Merkel
- Michael G. Hanna (ORCID: https://orcid.org/0000-0003-0825-4075)
- Catherine Summers
- Chafic Karam (ORCID: https://orcid.org/0000-0003-3868-2994)
- Laure Weijers (ORCID: https://orcid.org/0000-0003-1681-3826)
- Emily Jones (ORCID: https://orcid.org/0000-0001-6462-1234)
- Muriel Finkel (ORCID: https://orcid.org/0009-0007-7534-2207)
- Fran M Kochman
- Paula Schmitt (ORCID: https://orcid.org/0000-0002-1556-658X)
- Marieke Schurer
- Colleen Moffitt (ORCID: https://orcid.org/0009-0001-5561-9738)
- Nicola J. Mason (ORCID: https://orcid.org/0000-0002-6149-4927)
- Mathilde Puls
Institutions
- Cleveland Clinic (US)
- Alnylam Pharmaceuticals (United States) (US)
- Utrecht University (NL)
- Amyloidosis Foundation (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Orphanet Journal of Rare Diseases
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1186/s13023-024-03407-3
- Citations
- 10
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 2.34
Funders
- Alnylam Pharmaceuticals